https://www.nature.com/articles/d41586-025-01177-x Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. editorials 3. article High time to tackle drug-resistant fungal infections Download PDF * EDITORIAL * 15 April 2025 High time to tackle drug-resistant fungal infections To combat long-overlooked fungal pathogens, researchers and regulators must embrace innovative science and policy. * Twitter * Facebook * Email You have full access to this article via your institution. Download PDF A worker with hat and shorts and with a sprayer works in the field. There are concerns that the widespread use of fungicides to spray agricultural crops could lead to fungal resistance to similar compounds used in medicine.Credit: Andrii Yalanskyi/Getty Candida auris is a frightening yeast. It was first identified in 2009, in the inflamed ear canal of a Tokyo-based septuagenarian^1. Within a decade, researchers had found the yeast in ill people around the world. C. auris is often resistant to disinfectants and antifungal drugs, and can be difficult to kill. Between 30% and 60% of the people it infects will die. Around 3.8 million people die each year of infections caused by C. auris and other fungi. Annual deaths caused by fungal infections have nearly doubled in the past decade. [d41586-025] Understanding pathogen emergence through the lens of Candida auris Pathogenic fungi pose unique challenges, and overcoming them will require innovative approaches to both science and policy. Yet, despite the growing global threat posed by drug-resistant fungi, such infections rarely loom large in discussions of antimicrobial resistance. Two World Health Organization (WHO) reports published this month (see go.nature.com/3rniybw) -- the organization's first analyses of tests and treatments for fungal infections -- highlight the result of that neglect. Only three drugs to tackle the fungi that pose the biggest threat to human health are in late-stage clinical trials. Researchers, policymakers and industry must quickly act together to bolster the treatment pipeline and also to protect the potency of the antifungal drugs already in use. Severe fungal infections typically strike the most vulnerable, such as people with weakened immune systems or chronic respiratory conditions. Better, cheaper tests are needed to diagnose fungal infections in a timely way, and to determine whether the fungi responsible are drug-resistant. Diagnoses are often delayed, particularly in low- and middle-income countries, where fungal infections are common. This can lead to inappropriate treatment and contribute to resistance to antimicrobial drugs. Designing such drugs is also difficult. Fungal cells are more similar to human cells than to bacteria, suggesting that an antifungal compound could also be toxic to people. And lessons learnt from bacterial antimicrobial resistance do not always apply: when drug resistance emerges in fungi, it often does so through molecular mechanisms different from those that bacteria use to overcome antibiotics. Coloured scanning electron micrograph of Candida sp. cells. Candida yeast cells imaged with a scanning electron microscope. Credit: Steve Gschmeissner/SPL All of this means that it is crucial to invest in basic research to better understand which cellular pathways can be targeted in fungi without harming human cells. Last month, for example, researchers reported a compound made by bacteria that targets fungal cell membranes through a new mechanism, yet is relatively non-toxic to human cells grown in culture^2. Studies of fungal genetics, meanwhile, will be crucial to the detection of emerging pathogenic strains and drug resistance, as well as the design of new antifungal drugs. [d41586-025] New antifungal breaks the mould Drug-resistant fungal infections are fairly rare, making them difficult and expensive to study. What's more, people who contract serious fungal infections often have other health conditions that can make it hard to determine the safety of an experimental treatment. One way to facilitate clinical trials would be to establish clinical trial networks covering many institutions. These networks could standardize protocols and diagnostic tools, as well as drawing participants from a wide geographic area. Perhaps the biggest policy challenge will be to address a major potential source of drug resistance: agriculture. Some antifungal medicines are similar to the fungicides that farmers spray to protect crops, so the widespread use of fungicides could result in fungal resistance to similar compounds used in medicine. Overcoming this problem will require stakeholders to join together and find ways of protecting both food security and human health. Some countries are already taking steps in this direction. India has banned two antibiotics from being used for plant protection, because alternatives that pose less danger to human antimicrobials are available. The US Environmental Protection Agency has proposed including the risks of promoting resistance to antifungals in its assessment of the potential health impacts of new fungicides. [d41586-025] Global warming could drive the emergence of new fungal pathogens And, earlier this year, representatives of five European Union health and environmental agencies published a report on the threat that fungicide use in agriculture poses to a class of medicines used to treat infection with Aspergillus fungi^3. The compounds these drugs contain, called azoles, are also used in fungicides, veterinary medicines, wood preservatives and cosmetics. Aspergillus species are increasingly becoming resistant to them. The group highlighted several ways in which countries could act to preserve the utility of azoles. These included the effective management of agricultural and industrial waste, and adding fresh requirements to the approval process for azole fungicides. The agencies also advocated support for research into new fungicides that would not overlap with human treatments. Both the EU and the WHO reports have highlighted a litany of open research questions that must be addressed. It is now crucial that industry, government and philanthropic funders work together to give researchers the resources needed to fill these gaps. So far, scientists still have not determined what pushed C. auris to appear so rapidly in hospitals around the world. Genetic studies suggest that the yeast's ability to infect humans has evolved independently multiple times, in different regions. Some researchers worry that the conditions that encouraged this could nudge more fungi towards becoming dangerous. If so, it will be even more important to be prepared. Nature 640, 569 (2025) doi: https://doi.org/10.1038/d41586-025-01177-x References 1. Satoh, K. et al. Microbiol. Immunol. 53, 41-44 (2009). Article PubMed Google Scholar 2. Deng, Q. et al. Nature https://doi.org/10.1038/s41586-025-08678-9 (2025). Article Google Scholar 3. European Food Safety Authority et al. EFSA J. 23, e9200 (2025). PubMed Google Scholar Download references Reprints and permissions Related Articles * [d41586-025] New antifungal breaks the mould * [d41586-025] Read the paper: A polyene macrolide targeting phospholipids in the fungal cell membrane * [d41586-025] Understanding pathogen emergence through the lens of Candida auris * [d41586-025] Global warming could drive the emergence of new fungal pathogens Subjects * Microbiology * Medical research Latest on: Microbiology Natively expressed AcrIII-1 does not function as an anti-CRISPR protein Natively expressed AcrIII-1 does not function as an anti-CRISPR protein Matters Arising 16 APR 25 Reply to: Natively expressed AcrIII-1 does not function as an anti-CRISPR protein Reply to: Natively expressed AcrIII-1 does not function as an anti-CRISPR protein Matters Arising 16 APR 25 Bovine H5N1 binds poorly to human-type sialic acid receptors Bovine H5N1 binds poorly to human-type sialic acid receptors Matters Arising 16 APR 25 Medical research Reframe perspectives on Alzheimer's disease Reframe perspectives on Alzheimer's disease Outlook 16 APR 25 Why women experience Alzheimer's disease differently from men Why women experience Alzheimer's disease differently from men Outlook 16 APR 25 Japan's big bet on stem-cell therapies might soon pay off with medical breakthroughs Japan's big bet on stem-cell therapies might soon pay off with medical breakthroughs News Feature 16 APR 25 Nature Careers Jobs * Westlake University 'Frontiers of Life Sciences' International Undergraduate Summer School 2025 Westlake University 'Frontiers of Life Sciences' International Undergraduate Summer School 2025 Hangzhou, Zhejiang (CN) Westlake University [] * SCUT-GZIC Global Talent Recruitment Faculty position at SCUT. Guangzhou, Guangdong, China Guangzhou International Campus, South China University of Technology [] * Spaces: professor, associate professor, assistant professor Shenzhen, Guangdong (CN) The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) [] * Program Coordinator - Center of Excellence for Innate Immunity and Inflammation (CoE-III) Memphis, Tennessee St Jude children's Research Hospital [] * Full Professorship (W3) for Special Hematology (f/m/d) The Medical Faculty Mannheim of Heidelberg University offers the position of a Full Professorship (W3) for Special Hematology (f /m/d) to be f... Mannheim, Baden-Wurttemberg (DE) Medizinische Fakultat Mannheim der Universitat Heidelberg [] You have full access to this article via your institution. Download PDF Related Articles * [d41586-025] New antifungal breaks the mould * [d41586-025] Read the paper: A polyene macrolide targeting phospholipids in the fungal cell membrane * [d41586-025] Understanding pathogen emergence through the lens of Candida auris * [d41586-025] Global warming could drive the emergence of new fungal pathogens Subjects * Microbiology * Medical research Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * protocols.io * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Professional development * Nature Careers * Nature Conferences Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2025 Springer Nature Limited